Recombinant N-Acetyl-eglin C protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

N-Acetyl-eglin C is a potent protein inhibitor with a molecular mass of approximately 6.8 kDa. It interacts mechanically by binding tightly to serine proteases blocking their active sites and mitigating proteolytic activity. This protein also known as eglin C originates from medicinal leeches and is widely expressed in research settings for its inhibitory properties within protease studies. Its structure allows for strong and specific protease inhibition making it valuable in biochemical assays and in vivo models.

Biological function summary

Eglin C impacts various cellular processes by inhibiting proteases involved in inflammation and tissue remodeling. It actively participates in the control of extracellular matrix degradation aiding in wound healing and inflammation regulation. While eglin C does not form part of a larger protein complex its effects propagate through the modulation of enzymes that are essential to cellular homeostasis. This inhibition supports maintaining the balance of tissue growth and repair as it regulates enzymes that catalyze these processes.

Pathways

The actions of eglin C link closely to the inflammatory pathway and the tissue remodeling network. During inflammation eglin C modulates enzymes such as elastase and cathepsin impacting inflammatory signaling and subsequent tissue repair mechanisms. These pathways involve cytokine release and cell migration where eglin C's influence curbs excessive proteolytic degradation that could otherwise lead to tissue damage. Its relationship with these enzymes positions eglin C as an influential part of maintaining balanced inflammatory responses.

Florels suggest that eglin C could play roles in conditions like chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis (RA). In COPD the protease-antiprotease imbalance exacerbates tissue damage where eglin C's inhibition of elastase offers therapeutic potential. In RA eglin C targets the same pathways potentially reducing joint inflammation by inhibiting pathways involving elastase and other proteolytic enzymes. Through these engagements eglin C connects to proteins important in disease development providing a basis for exploring its therapeutic applications.